Fatty liver on computed tomography scan on admission is a risk factor for severe coronavirus disease

Okuhama, Ayako; Hotta, Masatoshi; Ishikane, Masahiro; Kawashima, Akira; Miyazato, Yusuke; Terada, Mari; Yamada, Gen; Kanda, Kohei; Inada, Makoto; Sato, Lubna; Sato, Mitsuhiro; Akiyama, Yutaro; Suzuki, T.; Nakamoto, Takato; Nomoto, Hidetoshi; Ide, Satoshi; Nakamura, Keiji; Saito, Sho; Iwamoto, Noriko; Yamamoto, Kei; Morioka, Shigefumi; Ujiie, Mugen; Hayakawa, Kayoko; Kustuna, Satoshi; Shida, Yoshitaka; Tajima, Tsuyoshi; Teruya, Katsuji; Funato, Yumi; Yamamoto, Makiko; Hojo, Masayuki; Sugiyama, Haruhito; Ohmagari, Norio

doi:10.1016/j.jiac.2021.10.013

Cited by 7 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… In the multivariate analysis, NAFLD was not associated with mortality in COVID-19 patients (OR 1.149; 95% CI: 0.669–1.976, p =0.614). Okuhama et al [ 40 ] 2022 222 Retrospective cohort Patients with severe COVID-19 had higher prevalence of fatty liver (OR 6.33; 95% CI: 3.37–12.14, p <0.001). In the multivariate analysis, fatty liver on CT-scan was significantly associated with severe COVID-19 (OR 6.20; 95% CI: 2.82–13.62, p <0.001).…”

Section: Discussionmentioning

confidence: 99%

“…To increase the relevance of the results from our study, we have performed additional searching process for studies which analyzed the relationship between NAFLD and COVID-19 outcomes (severity and mortality). We have found seven additional studies that published between 2021-2022 (Table 3) [38][39][40][41][42][43][44]. Out of seven studies, four of them were retrospective cohort, two were prospective cohort, and the remaining one study was case-control study.…”

Section: Original Articlementioning

confidence: 99%

See 1 more Smart Citation

Non-alcoholic fatty liver disease (NAFLD) and COVID-19 outcomes: A systematic review, meta-analysis, and meta-regression

Kurniawan

Hariyanto

2023

Narra J

View full text Add to dashboard Cite

It is important to identify risk factors for poor outcomes of coronavirus disease 2019 (COVID-19) patients. Currently, the correlation between non-alcoholic fatty liver disease (NAFLD) and COVID-19 outcomes has not been established. This study was conducted to determine the association between NAFLD and in-hospital outcomes of COVID-19 patients. The systematic searches were conducted by using PubMed and the Europe PMC databases and particular keywords were used as of December 10, 2020. Further searches were conducted up to 2022. All articles that include data about COVID-19 and fatty liver disease were collected. Statistical analysis was performed by using Review Manager 5.4 and Comprehensive Meta-Analysis version 3 software. A total of 7,210 COVID-19 patients from 18 studies were included in the final analysis. Meta-analysis revealed that NAFLD increased the risk of developing poor in-hospital outcome (pooled both severe disease and death) in COVID-19 patients (RR 1.42; 95%CI: 1.17–1.73, p<0.001, I2=84%, random-effect modeling). Subgroup analysis however found that having NAFLD only increased the chance of getting severe COVID-19 (RR 1.67; 95%CI: 1.32–2.13, p<0.001, I2=86%, random-effect modeling) and not mortality (RR 1.00; 95%CI: 0.68–1.47, p=0.98, I2=80%, random-effect modeling). Meta-regression suggested that age (p=0.001) and diabetes (p=0.029) were significantly influenced the relationship between NAFLD and in-hospital outcomes of COVID-19 (pooled both severe disease and mortality). The weaker association of NAFLD and in-hospital outcomes of COVID-19 was found for studies with median age ≥45 years old (RR 1.29) when compared to studies with median age <45 years old (RR 2.96). In addition, studies with the prevalence of diabetes ≥25% (RR 1.29) had a weaker association with in-hospital outcomes when compared to studies with diabetes prevalence <25% (RR 1.85). In conclusion, NAFLD increased the risk of chance of getting severe COVID-19 and therefore it should be evaluated closely to reduce the chance of getting severe COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Original Articlementioning

confidence: 99%

Non-alcoholic fatty liver disease (NAFLD) and COVID-19 outcomes: A systematic review, meta-analysis, and meta-regression

Kurniawan

Hariyanto

2023

Narra J

View full text Add to dashboard Cite

show abstract

“…Meanwhile, imaging techniques such as ultrasound or computed tomography (CT) are the primary tools used to identify the presence of fatty liver [ 57 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 ]. The use of a liver biopsy to confirm NAFLD is a rare occurrence in the literature [ 74 ].…”

Section: The Role Of Mafld In the Progression Of Covid-19mentioning

confidence: 99%

The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence

Buchynskyi

Kamyshna

Oksenych

et al. 2023

Viruses

View full text Add to dashboard Cite

The global population is currently experiencing the impact of the SARS-CoV-2 coronavirus, which has caused the Coronavirus Disease 2019 (COVID-19) pandemic. With our profound comprehension of COVID-19, encompassing the involvement sequence of the respiratory tract, gastrointestinal system, and cardiovascular apparatus, the multiorgan symptoms of this infectious disease have been discerned. Metabolic-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a pervasive public health concern intricately linked with metabolic dysregulation and estimated to afflict one-fourth of the global adult population. The burgeoning focus on the association between COVID-19 and MAFLD is justified by the potential role of the latter as a risk factor for both SARS-CoV-2 infection and the subsequent emergence of severe COVID-19 symptoms. Investigations have suggested that changes in both innate and adaptive immune responses among MAFLD patients may play a role in determining the severity of COVID-19. The remarkable similarities observed in the cytokine pathways implicated in both diseases imply the existence of shared mechanisms governing the chronic inflammatory responses characterizing these conditions. The effect of MAFLD on the severity of COVID-19 illness remains uncertain, as indicated by conflicting results in cohort investigations.

show abstract

“…Meanwhile, imaging techniques such as ultrasound or computed tomography (CT) are the primary tools used to identify the presence of fatty liver [48,57,[66][67][68][69][70][71][58][59][60][61][62][63][64][65]. The use of liver biopsy to confirm NAFLD is a rare occurrence in the literature [61].…”

Section: The Role Of Mafld In the Progression Of Covid-19mentioning

confidence: 99%

The Intersection of COVID-19 and MAFLD: An Overview of the Current Evidence

Buchynskyi¹,

Kamyshna²,

Oksenych³

et al. 2023

Preprint

View full text Add to dashboard Cite

The global population is currently experiencing the impact of the SARS-CoV-2 coronavirus, which has caused the Coronavirus Disease 2019 (COVID-19) pandemic. By our profound comprehension of COVID-19, encompassing the involvement sequence of the respiratory tract, gastrointestinal system, and cardiovascular apparatus, the multiorgan symptoms of this infectious disease have been discerned. Metabolic-associated fatty liver disease (MAFLD) is a pervasive public health concern, intricately linked with metabolic dysregulation and estimated to afflict one-fourth of the global adult population. The burgeoning focus on the association between COVID-19 and metabolic dysfunction-associated fatty liver disease (MAFLD) is justified by the potential role of the latter as a risk factor for both SARS-CoV-2 infection and the subsequent emergence of severe COVID-19 symptoms. Investigations have suggested that changes in both innate and adaptive immune responses among metabolic dysfunction-associated fatty liver disease (MAFLD) patients may play a role in determining the severity of COVID-19. The remarkable similarities observed in the cytokine pathways implicated in both diseases imply the existence of shared mechanisms governing the chronic inflammatory responses characterizing these conditions. The effect of metabolic dysfunction-associated fatty liver disease (MAFLD) on the severity of COVID-19 illness remains uncertain, as indicated by conflicting results in cohort investigations.

show abstract

Fatty liver on computed tomography scan on admission is a risk factor for severe coronavirus disease

Cited by 7 publications

References 20 publications

Non-alcoholic fatty liver disease (NAFLD) and COVID-19 outcomes: A systematic review, meta-analysis, and meta-regression

Non-alcoholic fatty liver disease (NAFLD) and COVID-19 outcomes: A systematic review, meta-analysis, and meta-regression

The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence

The Intersection of COVID-19 and MAFLD: An Overview of the Current Evidence

Contact Info

Product

Resources

About